CR
Christopher Ryan Sullivan
DELAYED 1 MONTH
Chief Financial Officer
Avalo Therapeutics, Inc.
Filings
4
Companies
1
Latest
May 21, 2026
Transactions
Signal
Ticker / Company
Insider
Transaction
Value
Filed
80
Avalo Therapeutics, Inc.
Christopher Ryan Sullivan
Chief Financial Officer
Sale
$448.8K
18,606 sh
May 11 8:05 PM
May 7, 2026
—
Avalo Therapeutics, Inc.
Christopher Ryan Sullivan
Chief Financial Officer
Option Exercise
$183.8K
18,606 sh
May 11 8:05 PM
May 7, 2026
82
Avalo Therapeutics, Inc.
Christopher Ryan Sullivan
Chief Financial Officer
Sale
$948.7K
47,000 sh
May 7 8:16 PM
May 6, 2026
—
Avalo Therapeutics, Inc.
Christopher Ryan Sullivan
Chief Financial Officer
Option Exercise
$377.9K
47,000 sh
May 7 8:16 PM
May 6, 2026
59
AVTX98% OUT
Avalo Therapeutics, Inc.
Christopher Ryan Sullivan
Chief Financial Officer
Sale
$111.9K
8,457 sh
May 1 8:37 PM
Apr 30, 2026
59
AVTX98% OUT
Avalo Therapeutics, Inc.
Christopher Ryan Sullivan
Chief Financial Officer
Sale
$110.7K
8,458 sh
May 1 8:37 PM
Apr 29, 2026